Teclistamab in patients with multiple myeloma and impaired renal function
- PMID: 37614153
- DOI: 10.1002/ajh.27063
Teclistamab in patients with multiple myeloma and impaired renal function
Abstract
Robust anti-myeloma activity with teclistamab in patients with severe renal impairment.
© 2023 Wiley Periodicals LLC.
References
REFERENCES
-
- Moreau P, Garfall AL, van de Donk N, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495-505.
-
- Dimopoulos MA, Sonneveld P, Leung N, et al. International myeloma working group recommendations for the diagnosis and Management of Myeloma-Related Renal Impairment. J Clin Oncol. 2016;34(13):1544-1557.
-
- TECVAYLI (teclistamab-cqyv) injection. Prescribing information. 2022 https://www.janssenlabels.com/package-insert/product-monograph/prescribi... 2023.
-
- Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacomet Syst Pharmacol. 2017;6(9):576-588.
-
- Mohan M, Chakraborty R, Bal S, et al. Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma. Br J Haematol. 2023. doi:10.1111/bjh.18909
Publication types
LinkOut - more resources
Full Text Sources